This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
6c5v
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==An anti-gH/gL antibody that neutralizes dual-tropic infection defines a site of vulnerability on Epstein-Barr virus== | ==An anti-gH/gL antibody that neutralizes dual-tropic infection defines a site of vulnerability on Epstein-Barr virus== | ||
| - | <StructureSection load='6c5v' size='340' side='right' caption='[[6c5v]], [[Resolution|resolution]] 4.80Å' scene=''> | + | <StructureSection load='6c5v' size='340' side='right'caption='[[6c5v]], [[Resolution|resolution]] 4.80Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[6c5v]] is a 5 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6C5V OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6C5V FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6c5v]] is a 5 chain structure with sequence from [http://en.wikipedia.org/wiki/Ebva8 Ebva8], [http://en.wikipedia.org/wiki/Ebvg Ebvg] and [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6C5V OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6C5V FirstGlance]. <br> |
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | ||
<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=PCA:PYROGLUTAMIC+ACID'>PCA</scene></td></tr> | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=PCA:PYROGLUTAMIC+ACID'>PCA</scene></td></tr> | ||
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">BXLF2, gH ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=10376 EBVG]), gL, BKRF2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=82830 EBVA8]), BZLF2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=10376 EBVG])</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6c5v FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6c5v OCA], [http://pdbe.org/6c5v PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6c5v RCSB], [http://www.ebi.ac.uk/pdbsum/6c5v PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6c5v ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6c5v FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6c5v OCA], [http://pdbe.org/6c5v PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6c5v RCSB], [http://www.ebi.ac.uk/pdbsum/6c5v PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6c5v ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| Line 19: | Line 20: | ||
</div> | </div> | ||
<div class="pdbe-citations 6c5v" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 6c5v" style="background-color:#fffaf0;"></div> | ||
| + | |||
| + | ==See Also== | ||
| + | *[[Antibody 3D structures|Antibody 3D structures]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: Ebva8]] | ||
| + | [[Category: Ebvg]] | ||
| + | [[Category: Human]] | ||
| + | [[Category: Large Structures]] | ||
[[Category: Gray, M A]] | [[Category: Gray, M A]] | ||
[[Category: McElrath, M J]] | [[Category: McElrath, M J]] | ||
Revision as of 09:31, 18 December 2019
An anti-gH/gL antibody that neutralizes dual-tropic infection defines a site of vulnerability on Epstein-Barr virus
| |||||||||||
Categories: Ebva8 | Ebvg | Human | Large Structures | Gray, M A | McElrath, M J | McGuire, A T | Ortego, M S | Pancera, M | Structural genomic | Snijder, J | Stuart, A B | Veesler, D | Weidle, C | Epstein-barr virus | Gh/gl | Glycoprotein | Neutralizing antibody | Ssgcid | Viral protein
